Mead Johnson (MJN) 8-K Raises Eyebrows at JPMorgan

Shares of Mead Johnson Nutrition (NYSE: MJN) are mildly higher mid-day after JPMorgan analyst Ken Goldman highlighted the company's recent 8-K. While the filing didn't attract much attention, Goldman said it warrants some.

In the filing, Mead changed its stock award and incentive plan to render a change of control more favorable to high level employees. Goldman sees the change as potentially notable given today’s heightened M&A environment across their coverage.

The firm maintained an Overweight rating and price target of $93 on MJN.

For an analyst ratings summary and ratings history on Mead Johnson Nutrition click here. For more ratings news on Mead Johnson Nutrition click here.

Shares of Mead Johnson Nutrition closed at $89.19 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Macquarie Group Ltd. (MQG:AU) (MQBKY) to Overweight
• Loop Capital Starts Samsara Inc (IOT) at Buy, 'Play on AI, ML, & IoT Tech Themes in Asset Intensive Industries'
• Sage Therapeutics (SAGE) PT Lowered to $16 at TD Cowen